On Demand 2016 Practice Essentials: Immunotherapy and Practice Management

This package is a collection of the presentations from Thursday's Practice Essentials program.

Credits/pricing
5.25 AMA PRA Category 1 Credit(s)TM
$84 $67 College members, $127 $101 non-members

Release Date: 12/01/2016
Expiration Date: 11/30/2019

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 5.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

  • Discuss the early concepts of immunotherapy and how what we currently do was based on the research of Noon
  • Review current indications for subcutaneous and sublingual immunotherapy and best practice of allergen immunotherapy
  • Discuss prospective innovations in allergy immunotherapy
  • Describe the proper coding for appropriate billing to optimize reimbursement
  • Discuss the new payment models and understand how other regulatory changes are impacting allergy practice
  • Interpret allergy-specific compensation and production data (RVUs)
  • Analyze allergists’ beliefs on fairness in compensation and career satisfaction
  • Critique allergists’ productivity in the workplace
Additional information
Disclosure: 

John J. Oppenheimer, MD, FACAAI, Moderator -- Consultant/Advisor: AstraZeneca, Genentech, GlaxoSmithKline, Meda, Mylan, Novartis, Annals of Allergy, ABAI, Up to date, Teva; Supported/ Contracted Research: AstraZeneca, Genentech, MedImmune, Sanofi

Harold S. Nelson, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Circassia, Merck; Supported/Contracted Research: Circassia

Jonathan Corren, MD -- Supported/Contracted Research: Amgen

Mark Larche, PhD -- Consultant/Advisor: AbbVie, Circassia, Aravax Pty, UCB, Adiga Life Sciences Inc; Supported/Contracted Research: Circassia, Adiga Life Sciences Inc; Patent Holder/Royalty/IPR: Circassia; Ownership Interest: Circassia

Stephen R. Durham, MD -- Consultant/Advisor: Boehringer Ingelheim, Circassia, Merck, Biomay, Anergis; Speaker: ALK, PneumoUpdate Gmbh; Supported/Contracted Research: ALK, Merck, Regeneron

Stanley M. Fineman, MD, MBA, FACAAI, Moderator -- Consultant/Advisor: Aimmune; Speaker: AstraZeneca, Boehringer Ingelheim, Genentech, Greer, Meda, Novartis, Nestle, Teva; Supported/Contracted Research: DBV Technologies, Genentech, Greer, Meda, Aimmune, Stallergenes

J. Allen Meadows, MD, FACAAI -- Speaker: Meda

James M. Tracy, DO, FACAAI -- Consultant/Advisor: Shire; Speaker: UptoDate

Michael S. Blaiss, MD, FACAAI -- Consultant/Advisor: Response Scientific, JDP Therapeutics, Pfizer; Ownership Interest: AllergyZone, Response Scientific, JDP Therapeutics

The following have no financial relationship to disclose:

Kari C. Nadeau, MD, PhD

Kay Tyler, BS, BA, MBA

Gary N. Gross, MD, FACAAI

 

Course summary
Available credit: 
  • 5.25 AMA PRA Category 1 Credit™
  • 5.25 Attendance
Course opens: 
11/12/2016
Course expires: 
11/30/2019
Cost:
$101.00
Rating: 
0

Available Credit

  • 5.25 AMA PRA Category 1 Credit™
  • 5.25 Attendance

Price

Cost:
$101.00
Please login or create an account to take this course.